MedPath

evothyroxine for euthyroid women with recurrent miscarriage and positive TPO antibodies: a randomized controlled trial

Phase 3
Completed
Conditions
recurrent miscarriage
thyroid autoimmunity
10043739
10000211
Registration Number
NL-OMON44997
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Trial ended prematurely

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
160
Inclusion Criteria

1.Women with unexplained RM and thyroid autoimmunity. Recurrent miscarriage is defined as two or more miscarriages.TPOAb positivity is defined according to the cut off levels of the coordinating or cooperating centres.
2.Age 18 - 42 years at randomisation
3.Willing and able to give informed consent (IC).

Exclusion Criteria

1.Antiphospholipid syndrome (lupus anticoagulant and/ or anticardiolipin antibodies [IgG or IgM]) and/ or B2-Glycoprotein IgG or IgM)
2.Other auto-immune conditions, diabetes mellitus, diabetes gravidarum, thyroid disease different then isolated thyroid autoimmunity.
3. Abnormal TSH. This is defined as a TSH level different then the centre specific cut- off levels. ( Known thyroid disease different then isolated thyroid autoimmunity)
4.Previous enrolment in the T4LIFE- trial
5. Contraindications to levothyroxine use:
Adrenal or pituitary disorders, untreated
Thyreotoxicosis, untreated
Acute cardiac arrest
Acute pancreatitis
Acute myocarditis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath